DuoDote® Auto-Injector

(atropine and pralidoxime chloride injection)

 
 

You Are Now Leaving the MeridianMeds.com Website

Links to other sites are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

CANCEL
Product image Mobile: 

Use DuoDote in the presence of life-threatening poisoning by organophosphorous nerve agents.

Learn more about DuoDote and the different kinds of nerve agent poisonings it treats in our presentation.5

Product indication: 

Indication:

DuoDote (atropine and pralidoxime chloride injection) Auto-Injector is indicated for the treatment of poisoning by organophosphorous nerve agents as well as organophosphorous insecticides.

 

Product Especification: 
To order or request a quote, call 1-800-638-8093
Key Product Specifications6:
NSN6505-01-581-1327
NDC11704-620-01
Delivers2.1 mg atropine in 0.7 mL and 600 mg pralidoxime chloride in 2 mL sequentially through a single needle using the two-chambered BinaJect® drug delivery system.
Length of Unit145 mm
Diameter of Unit19 mm
Needle Gauge23
Needle Length21 mm
Administration TypeIntramuscular injection
Packaged1 auto-injector per box with instructions; package insert
Packaging for Shipping30 units per shipper box (286 mm x 213 mm x 210 mm), weighing 2.3 kg
StorageStore at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep from freezing. Protect from light.
Prescription RequiredYes

 

For medical: 

For medical questions concerning Meridian products, to report an adverse event, or to speak to a member of Pfizer US Medical Information, call 1-800-438-1985.

Product image Desktop: 
Product trademark: 
View full Prescribing Information for DuoDote® Auto-Injector (atropine and pralidoxime chloride injection) ORDER OR REQUEST A QUOTE Learn more in our presentation
DuoDote® and BinaJect® are registered trademarks of Meridian Medical Technologies, Inc., a Pfizer company.

 

Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION AND INDICATION

DuoDote® Auto-Injector (atropine and pralidoxime chloride injection)

In the presence of life-threatening poisoning by organophosphorous nerve agents or insecticides there are no absolute contraindications to the use of DuoDote.

The DuoDote Auto-Injector should be administered by emergency medical services personnel who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication. It is intended as an initial treatment of the symptoms of organophosphorous nerve agent or insecticide poisoning; definitive medical care (eg, hospitalization, respiratory support) should be sought immediately.

Individuals should not rely solely upon agents such as atropine and pralidoxime to provide complete protection from organophosphorous nerve agents and insecticide poisoning. Primary protection against exposure to organophosphorous nerve agents and insecticides is the wearing of protective garments, including masks designed specifically for this use. Evacuation and decontamination procedures should be undertaken as soon as possible. Medical personnel assisting evacuated victims of organophosphorous nerve agent or insecticide poisoning should avoid contaminating themselves by exposure to the victims’ clothing.

When symptoms of poisoning are not severe, DuoDote should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial infarction, severe narrow-angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal insufficiency, chronic pulmonary disease, or hypersensitivity to any compound of the product.

No more than three doses should be administered unless definitive medical care is available.

Elderly people and children may be more susceptible to the effects of atropine. It is not known whether pralidoxime or atropine can cause fetal harm when administered to a pregnant woman or if they can affect reproductive capacity. Atropine readily crosses the placental barrier and enters the fetal circulation. DuoDote should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. DuoDote safety and effectiveness in children have not been established.

Muscle tightness and sometimes pain may occur at the injection site. The most common adverse effects of atropine can be attributed to its antimuscarinic action and include dryness of mouth, blurred vision, dry eyes, photophobia, confusion, headache, and dizziness, among others. Pralidoxime chloride’s adverse effects include changes in vision, dizziness, headache, drowsiness, nausea, tachycardia, increased blood pressure, muscular weakness, dry mouth, emesis, rash, dry skin, hyperventilation, decreased renal function, excitement, manic behavior, and transient elevation of liver enzymes and creatine phosphokinase. When atropine and pralidoxime are used together, the signs of atropinization may occur earlier than might be expected when atropine is used alone.

Indication:

DuoDote (atropine and pralidoxime chloride injection) Auto-Injector is indicated for the treatment of poisoning by organophosphorous nerve agents as well as organophosphorous insecticides.